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Object. The criteria for remission of acromegaly following transsphenoidal adenoma resection are in evolution. In 
the present study the authors evaluate the utility of predicting long-term remission by reference to a single fasting 
growth hormone (GH) level on the 1st postoperative day.
Methods. A retrospective analysis was conducted on 181 patients with acromegaly who underwent transsphenoidal 
resection between 1973 and 1990 and completed a 5-year follow-up period. Fasting serum GH levels were obtained in 
all patients on the 1st postoperative day in the absence of exogenous glucocorticoids. All patients participated in a fol­
low-up evaluation lasting at least 5 years, which included measurements of serum insulin-like growth factor-I (IGF-I) 
levels as an index of acromegalic activity.
Among the 181 patients, GH levels ranged from 0 to 8 ng/ml in 131 (72%) on the 1st postoperative day, suggest­
ing biochemical remission. This group included 107 (84%) of the 127 patients with microadenomas, but only 24 (44%) 
of the 54 with macroadenomas. Nevertheless, 15 (11%) of the 131 patients who initially had attenuated GH levels dis­
played recurrent acromegaly within the first 2 years (with elevated levels of IGF-I in all cases, and abnormalities ap­
pearing on magnetic resonance images in nine cases). Only one of 116 patients in whom the initial postoperative GH 
level was lower than 2 ng/ml experienced a recurrence, whereas 14 (93%) of the 15 patients with postoperative GH 
levels between 2.2 and 8 ng/ml subsequently displayed biochemical evidence of acromegaly.
Conclusions. The findings indicate that a fasting morning serum GH level lower than 2 ng/ml on the 1st postoper­
ative day portends long-term biochemical remission of acromegaly, whereas higher levels are a significant marker for 
recurrent disease.
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The generally accepted criteria for predictive assessment 
of long-term remission of acromegaly are in evolution.3611, 
22,23,41,42 Several biochemical tests have been proposed in the 
postoperative period, including measurements of basal GH, 
mean GH, and IGF-I, as well as the GH responses to an oral 
glucose load and TRH. Each of these tests has limited value 
in predicting long-term remission, especially with the ad­
vent of novel ultrasensitive GH assays. We therefore evalu­
ated the utility of predicting long-term biochemical remis­
sion by reference to a single fasting GH level on the 1st 
postoperative day.
C lin ic a l  M a t e r ia l  a n d  M e t h o d s
From October 1973 until August 1990, 205 patients with 
acromegaly were surgically treated at the Department of 
Neurosurgery of the University of Southern California 
School of Medicine. Patient records were retrospective­
ly reviewed for data from a detailed history and physical 
examination, neuroophthalmological evaluation where ap­
propriate, neuroradiological reports, operative notes, histo-
A crom egaly , which is caused by a GH-secreting 
pituitary adenoma in an overwhelming majority 
(99%) of cases,26 is a clinical syndrome associat­
ed with significant risks of morbidity and mortality. Left 
untreated, the mortality rate is greater than that for age- 
matched controls and deaths occur from complications in­
cluding hypertension, cardiac disease, diabetes, pulmonary
disorders, and associated malignancies.13,41,42,44,45,49,56 Micro-
surgical adenomectomy, performed by a transsphenoidal 
approach, has evolved to be the most common first-line 
treatment modality for acromegaly.1,2,4,10,14,18,20,25,32,35,39,46,48, 
49,51,52 Radiation therapy and pharmacotherapy with the so­
matostatin analog octreotide are useful nonsurgical options 
or adjuncts.41,42 The determination of a cure in the postoper­
ative period is used to direct subsequent management and 
follow-up regimens that are costly and may require addi­
tional biochemical testing, imaging, and initiation of phar­
macotherapy.
Abbreviations used in this paper: GH = growth hormone; IGF-I = 
insulin-like growth factor-I; OGTT = oral glucose tolerance test; 
TRH = thyrotropin-releasing hormone.
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TABLE 1
Normal values of IGF-I detected by radioimmunoassay, as 
stratified by age and sex
Normal IGF-I Levels (ng/ml)







> 18 90-318 116-270
pathological reports, pre- and postoperative endocrinologi­
cal studies, and follow-up clinic reports.
Of a total of 205 patients, 181 (88%) were identified who 
had completed a 5-year follow-up period and this group 
formed the basis for this study. Seventeen patients (8%) did 
not complete 5 years of follow up and seven patients (3%) 
died of complications of their acromegaly before the end of 
the 5-year period. These 24 patients were excluded from the 
study. All patients underwent a preoperative history and 
physical examination, an imaging study (sellar polytomog­
raphy plus pneumoencephalography and/or angiography 
between 1973 and 1976; computerized tomography scan­
ning between 1976 and 1982, or magnetic resonance imag­
ing between 1982 and 1990), an assessment of pituitary 
function including a fasting GH level and documentation 
of the GH nadir following a 75-mg glucose load and/or the 
response of GH to TRH stimulation, and a neuroophthal- 
mological examination whenever indicated.
All patients underwent transnasal transsphenoidal resec­
tion of their tumors, which was performed using standard 
techniques.17 Glucocorticoids were not administered during 
the immediate postoperative period. A fasting serum GH 
level was obtained in all patients at 7 a.m. on the morning 
after surgery.
Patients were again evaluated at 6 and 12 weeks post­
operatively, and every 6 months thereafter. At each of these 
visits, an assessment of the patient’s acromegalic status 
was obtained, including the fasting GH level between 1973 
and 1984, or the serum IGF-I during subsequent years once 
the appropriate assay became available. Because of the 
length of the follow-up period, IGF-I measurement was ob­
tained in all patients one or more times during the follow- 
up period.
R e s u lt s
Demographic Data
The age range of the patients was 8 to 63 years. The study 
included 94 male (52%) and 87 (48%) female patients. One 
hundred twenty-seven patients (70%) had microadenomas 
(< 10 mm) and 54 (30%) harbored macroadenomas (^  
10 mm).
Preoperative Endocrine Status
The 181 patients included in this study all presented with 
the classic signs and symptoms of acromegaly. Preoperative
TABLE 2
Relationship between intermediate postoperative GH levels 
(2.2-8 ng/ml) and final IGF-I level
Tumor Size
Initial Postop GH 
Level (ng/ml)
Last IGF-I Level 
















endocrinological testing among the 127 patients with mi­
croadenomas revealed elevated GH levels or failure of GH 
suppression in response to glucose loading; in no case was 
the fasting GH elevated above 40 ng/ml. Similarly, 24 pa­
tients harboring macroadenomas were found to have GH 
levels less than 40 ng/ml, whereas in 30 patients with mac­
roadenomas (56% of all macroadenomas) the fasting GH 
levels were greater than 40 ng/ml.
Short-Term Endocrine Outcome
The major variable examined was the postoperative Day
1 fasting morning serum GH level. In our laboratory, hu­
man GH is analyzed using a diagnostic immunochemilumi- 
nescence kit (Nichols Institute Diagnostics, San Clemente, 
CA) that utilizes a primary monoclonal antibody. Normal 
values are reported to be 0 to 8 ng/ml. Of the 181 patients 
studied, in 131 (72%) the GH levels were lower than 8 ng/ 
ml on the 1st postoperative day. These included 107 (84%) 
of the 127 patients with microadenomas and 24 (44%) of 
the 54 with macroadenomas. Stratification of these results 
revealed that intermediate values of GH, ranging from 2.2 
to 8 ng/ml, were measured in 15 of these patients (8% of the 
total, eight microadenomas and seven macroadenomas); in 
the remaining 116 patients GH values lay within the range 
of less than 0.5 to 2 ng/ml.
Long-Term Clinical and Endocrine Outcome
To assess long-term outcome, we measured the patient’s 
serum IGF-I level at the end of a follow-up period that last­
ed at least 5 years. Our laboratory performs a radioimmuno­
assay procedure, in which the i G F -I in the unknown spec­
imen competes with a known quantity of radioactively 
labeled IGF-I for binding sites on a specific antibody. The 
normal IGF-I values used were age and sex stratified (Ta­
ble 1). In all cases, a normal IGF-I level at this 5-year inter­
val correlated with complete remission of most reversible 
symptoms of acromegaly. Using the results of this test as 
our outcome marker, we found that 115 (99%) of the 116 
patients with a Day 1 postoperative GH less than 2 ng/ml 
exhibited a sustained normal IGF-I level. Only one patient
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with a macroadenoma was found to have biochemical evi­
dence of persistent disease, despite the low postoperative 
GH value. Of the 15 patients with intermediate values of 
GH (2.2-8 ng/ml), only one patient who harbored a micro­
adenoma and had a Day 1 postoperative fasting GH of 3.6 
ng/ml appears to have attained a long-term biochemical re­
mission of his disease (Table 2). If the standard for re­
mission is considered to be a value of less than 2 ng/ml, this 
patient would be considered to be in remission (by IGF-I 
criteria) despite the fact that the early GH level was high.
Ninety-nine percent of patients in whom the Day 1 fast­
ing serum GH was lower than 2 ng/ml experienced sus­
tained long-term normalization of their IGF-I level, where­
as 93% (14 of 15) of patients with GH levels less than 8 
ng/ml but greater than 2 ng/ml did not experience remission 
of their disease (Table 3). In nine of the latter patients, com­
puterized tomography or magnetic resonance images dem­
onstrated a residual sellar mass. Twelve of these patients re­
ceived radiation therapy; in two cases, this therapy resulted 
in normalization of the patient’s IGF-I level within 2 years. 
One patient underwent a second surgery at another institu­
tion, which did not result in an alteration in either the GH or 
IGF-I levels.
Of the seven patients who died of acromegaly before 
completion of a 5-year follow-up evaluation, all harbored 
macroadenomas preoperatively and none had postoperative 
GH values less than 8 ng/ml. All these patients were treat­
ed with external beam radiation (5000 cGy) for residual tu­
mor without normalization of GH or IGF-I levels (when 
available) levels during follow up.
D is c u s s io n
Transsphenoidal Surgery in Acromegaly
Transsphenoidal microsurgical adenomectomy is cur­
rently the accepted first-line therapy for GH-secreting tu­
mors encountered in patients with acromegaly.1'2'4101418'20'24, 
25,32,35,39,4i,42,46,48,49,5i5  a  large combined analysis of 1360 pa­
tients with acromegaly conducted by Ross and Wilson46 
documented an overall postoperative cure rate of 60.4%. 
An even higher rate of cure can be found for microade­
nomas, exceeding 76 to 84% in a recent large surgical se­
ries 2'14'18'20'37,39'41,51'52
In the current series, we deemed 78% of the microadeno­
mas and 31% of the macroadenomas to be in long-term bio­
chemical remission, with an overall remission rate of 64%. 
These rates were determined using very stringent criteria 
for remission: a postoperative GH level less than or equal to
2 ng/ml, a normal age- and sex-matched 5-year IGF-I level, 
and clinical evidence of disease remission at 5 years. This 
long-term follow up and use of three stringent criteria, in­
cluding a clinical correlation, is unique in the literature con­
cerning acromegaly.
It should be noted that 205 patients were initially treat­
ed, but 24 were excluded from the study due to the lack of 
a 5-year follow up. This number includes seven patients 
harboring macroadenomas who died before they could par­
ticipate in the 5-year follow up. All these patients had post­
operative GH levels greater than 8 ng/ml, and all had elevat­
ed IGF-I levels before their deaths. If these patients were to 
be included, the overall cure rate would decrease to 62%
TABLE 3
Relationship between immediate postoperative level of GH and 
outcome in patients with acromegaly stratified by size of lesion*
Type of Lesion Total No. Patients W/ Normal Patients W/ Elevated
& GH Level of Patients Level of IGF-I Level of IGF-I
patients w / microadenomas (127patients)
< 2  ng/ml GH 99 99 0
2-8  ng/ml GH 8 1 7
> 8  ng/ml GH 20 0 20
patients w / macroadenomas (54 patients)
2 ng/ml GH 17 16 1
2-8  ng/ml GH 7 0 7
8 ng/ml GH 30 0 30
* Final outcome determined by level of IGF-I measured 5 years postop­
eratively.
and the cure rate for macroadenomas would drop to 28%. 
There would be no effect on the GH study results, howev­
er, because in all patients the postoperative GH levels were 
elevated.
Seventeen patients were lost to follow up before the 
5-year follow up was completed. Twelve patients had mi­
croadenomas; in 10 of these, the GH levels were lower than
2 ng/ml and the IGF-I levels were either normal or un­
known at follow up. In two patients the GH levels were 
higher than 2 ng/ml and the IGF-I levels were unknown. 
Five patients had macroadenomas: in two of these the GH
levels were less than 2 ng/ml and IGF-I levels were normal
at a limited follow up; in the other three patients the GH lev­
els were elevated and the early IGF-I levels were elevat­
ed or unknown. It is unlikely that addition of these patients
would substantially change the overall results of this study.
Treatment for Patients in Whom Transsphenoidal Surgery
has Failed
The initial treatment of choice for the typical patient har­
boring a GH-secreting pituitary adenoma is resection. The
management dilemma arises for the patient with persistent
disease activity despite surgery. A repeated operation has 
a low rate of success (19% in one series39) and a higher 
rate of complication (19% suffered serious local complica­
tions and 63% had surgically induced hypopituitarism in 
the large series of Long, et al.,39 significantly higher than 
that seen in primary transsphenoidal surgery). Thus, where­
as some authors advocate additional exploratory surgery 
under certain conditions,2046 others do not.6,24,52
Radiation therapy significantly lowers postoperative GH 
levels in a large number of patients with refractory disease
(a 50-79% response is commonly cited8'15'28-3134 36'43'53), but it 
can take as long as 10 years to have a significant effect, dur­
ing which time the patient continually experiences the dele­
terious effects of GH excess. Medical therapy with the do­
pamine agonist bromocriptine or the somatostatin analog 
octreotide lowers GH levels in many patients, but these 
medications are often poorly tolerated and rarely result in a 
cure of the disease process.9,33,55 Adjuvant therapies for per­
sistent or recurrent disease thus have significant limitations 
due to morbidity and the low rate of disease control. This 
fact, coupled with the serious long-term rates of morbidity 
and mortality associated with unrecognized persistent dis­
ease, makes it crucial for the treating physician to determine
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whether the patient who has undergone the initial surgery is 
likely to experience a sustained remission.
Defining Chemical Control
The accepted standards of what constitutes chemical con­
trol of acromegaly are evolving.11,23,40-42 The most advan­
tageous laboratory test would correlate closely with dis­
ease activity. Recent studies have led to the consideration of 
IGF-I as the best marker for biochemical control. The pro­
duction of IGF-I, a peptide whose plasma concentration is 
largely attributable to hepatic release, but which is found in 
many tissues, is the major determinant of acromegalic ac-
tivity.3,6,7,16,19,22,27,41 Although GH stimulates the production
and release of IGF-I, controversy exists as to the log-linear 
correlation of GH and IGF-I levels. Nevertheless, it seems 
that the major end-tissue effects of cellular proliferation are 
directly mediated by IGF-I.41,47 Unfortunately, measuring 
IGF-I during the early postoperative period does not accu­
rately reflect GH status because IGF-I levels take sever­
al weeks to return to baseline level after successful tumor 
resection.27 Furthermore, the systemic insult of surgery 
and calorie deprivation may also lower IGF-I levels. Thus, 
measuring this peptide is not helpful in determining a post­
operative management course. Additionally, the IGF-I im­
munoassay is relatively costly, more than $80 at our institu­
tion as compared with $14 to determine a serum GH level. 
Thus, although we have observed that an IGF-I level at 
5 years correlates closely with disease activity and accurate­
ly assesses the patient’s ultimate acromegalic status, it is 
an imprecise test when used during the early postoperative 
period.
Historically, determination of the serum GH level has 
been the most commonly used test of acromegalic activity. 
Two major problems exist when using GH levels to de­
termine postoperative acromegalic activity, however. First, 
GH secretion is pulsatile, varying greatly among individ­
uals and achieving transient levels as high as 30 ng/ml in 
healthy people.41 Second, GH has a relatively short serum 
halflife (~ 20 minutes), thus allowing the possibility that an 
isolated measurement may not be indicative of the true 
physiological status of the patient.41,50 Twenty-four hour in­
tegrated mean GH measurements are therefore more ac­
curate, but require considerable effort and expense. Other 
tests, such as the OGTT and the TRH stimulation test have 
been performed and usually suppress GH in patients who
have been cured.3,5,6,19,22,38,41,51,54 Recent consensus has sug­
gested that an OGTT in which the nadir GH level is less 
than 1 ng/ml following oral glucose loading, together with 
a normal sex- and age-matched IGF-I level should be used 
to define chemical control following either medical or sur­
gical treatment.23
Unfortunately, administration of an OGTT during the 
early postoperative period may be impractical and, for rea­
sons previously stated, IGF-I measurement may be unreli­
able. In the present study we evaluated the predictive value 
of an early postoperative serum GH level. If GH measure­
ments are to be used, a specific reproducible value should 
be determined that distinguishes patients at risk for persis­
tent or recurrent disease activity from those who are truly 
cured. The trend in the literature has been toward a progres­
sive lowering of the value accepted as indicative of disease 
control. In the last 15 years, various reports have increased
this stringency from 10 to 8 to 5 ng/ml.3,32,35384142,51,52 In a 
recent study the authors examined a postoperative GH level 
of 3 ng/ml as prognostic for control, but found an 11% re­
currence rate using this criterion.21
A further lowering of the level constituting remission 
is supported by the observation that half of all patients in 
whom the postoperative GH level is below 5 ng/ml still 
have elevated IGF-I levels,6,23 whereas five of six patients 
with GH levels between 2 and 5 ng/ml were found to have 
elevated IGF-I in another series (although only two of these 
patients had evidence of persistent disease activity).38 Thus, 
these more recent studies support a GH level of less than 2 
ng/ml as predictive of disease control.
The observation of an elevated IGF-I level with no clini­
cal evidence of persistent disease in the series reported by 
Levitt and associates38 indicates the key issue underlying 
this point in question; that is, correlation of measurable in­
dicators of acromegalic activity with the risks of morbidity 
and mortality associated with the disease process itself. Un­
fortunately, no article in the literature has documented the 
association between IGF-I concentrations and mortality.38 
Nevertheless, compelling evidence now confirms that se­
rum GH levels are the single most important determinants 
of death rates.45 Bates and colleagues12 found that 48 pa­
tients with acromegaly in whom mean GH levels were be­
tween 2.5 and 5 ng/ml had mortality rates double those for 
age-matched controls, whereas 31 patients with acromegaly 
in whom mean GH levels were less than 2.5 ng/ml were not 
at increased risk. Although patients with GH levels between
2 and 2.5 ng/ml may not be at increased risk for death, they 
are at risk for recurrence, given the data of the current study.
The present study shows that an immediate GH level of 
less than or equal to 2 ng/ml is indicative of long-term sur­
gical success (as verified by 5-year IGF-I levels) and can be 
used to make an accurate prediction in 99% of cases. De­
spite the acknowledged limitations of postoperative GH 
testing, this result is borne out over this large series of 181 
patients with prolonged follow up of at least 5 years.
C o n c lu s io n s
The findings of this study indicate that a fasting serum 
GH level lower than 2 ng/ml on the 1st postoperative day 
predicts biochemical remission of acromegaly. Although 
an IGF-I measurement is a bioactive indicator of long-term 
disease control, an immediate postoperative GH level pro­
vides a simple, inexpensive, and reliable assay for deter­
mining the rational postoperative management of these pa­
tients.
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